NASDAQ:AVEO AVEO Pharmaceuticals (AVEO) Stock Price, News & Analysis → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free AVEO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$14.99▼$15.0050-Day Range$14.90▼$15.0052-Week Range$3.06▼$15.00Volume247,800 shsAverage Volume601,442 shsMarket Capitalization$521.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get AVEO Pharmaceuticals alerts: Email Address Ad Paradigm PressAI “wealth window” is closing soon!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… About AVEO Pharmaceuticals Stock (NASDAQ:AVEO)AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Read More Ad Paradigm PressAI “wealth window” is closing soon!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… AVEO Stock News HeadlinesMarch 28, 2024 | forbes.comKorean Conglomerate LG To Invest $74 Billion In AI, Biotech, Cleantech And Other Growth AreasMarch 28, 2024 | globenewswire.comCORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeApril 17, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 25, 2024 | finanznachrichten.deAVEO Pharmaceuticals, Inc.: AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeMarch 25, 2024 | globenewswire.comAVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory CommitteeMarch 12, 2024 | finance.yahoo.comNeuroendocrine Tumor Treatment Market revenue to hit USD 8 Billion by 2035, says Research NesterMarch 6, 2024 | msn.com2024 Chevrolet Aveo: Driving The Compact Expat In Mexico CityNovember 30, 2023 | finance.yahoo.comAVEO Oncology, an LG Chem company, Earns Spot on Boston Globe's 2023 Top Places to Work List for Second Consecutive YearApril 17, 2024 | Priority Gold (Ad)Biden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...November 3, 2023 | finance.yahoo.comActinium Appoints Lynn Bodarky as Chief Business OfficerOctober 30, 2023 | afr.comBrookfield finalises $1.45b debt refi for Aveo; lenders pile inJuly 13, 2023 | afr.comBrookfield locks in $1.45b debt refi for Aveo; five banks underwriteMay 10, 2023 | finance.yahoo.comActinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals DayMay 5, 2023 | marketwatch.com2023 Kidney Cancer Market Size Growth Analysis by Absolute Reports | with [101 Pages] and Forecast till 2031May 3, 2023 | marketwatch.comC-MET & HGF Inhibitors Market Growth Opportunities and Emerging Trends till 2031May 3, 2023 | marketwatch.comFGF-2 Inhibitors Market 2023 SWOT Analysis and Demand Status Forecast by 2030April 27, 2023 | marketwatch.comC-MET / HGF Inhibitors Market Size [2023] Global Overview includes Market Trends and Forecast to 2027 | with [148 Pages]April 27, 2023 | marketwatch.comHepatocyte Growth Factor Market Research Analysis 2023-2031April 25, 2023 | marketwatch.comNeuroendocrine Tumors Treatment Market 2023 to 2030 Market Analysis, Share, Size, Trends, Scope, Growth Drivers, By Top Companies And ForecastApril 23, 2023 | marketwatch.com2023-2030 Kidney Cancer Treatment Drugs Market Share, Detailed Examination of Industry Trends and OpportunitiesApril 20, 2023 | marketwatch.comIndustry Research Report on C-MET / HGF Inhibitors Market Share and Industrial Overview till 2030April 16, 2023 | marketwatch.comC-MET / HGF Inhibitors Market Forecast to 2030April 14, 2023 | msn.com2024 Chevy Aveo: The Sonic Is Still Alive and Thriving, Just Not in the U.S.April 12, 2023 | marketwatch.comC-MET & HGF Inhibitors Market Growth by 2030April 7, 2023 | marketwatch.com2023 Cancer Drug Therapy Market: Projection up to 2027April 5, 2023 | marketwatch.comKidney Cancer Drugs Market 2023 Size and Forecast to 2031April 3, 2023 | thestreet.comAVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing AgreementSee More Headlines Receive AVEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today4/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:AVEO CUSIP05358810 CIK1325879 Webwww.aveooncology.com Phone(617) 400-0101Fax617-995-4995Employees114Year Founded2001Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,340,000.00 Net Margins-30.79% Pretax Margin-30.79% Return on Equity-81.66% Return on Assets-28.83% Debt Debt-to-Equity Ratio0.94 Current Ratio2.37 Quick Ratio2.35 Sales & Book Value Annual Sales$42.29 million Price / Sales12.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book11.28Miscellaneous Outstanding Shares34,763,000Free Float33,619,000Market Cap$521.45 million OptionableOptionable Beta1.00 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMichael P. BaileyPresident, Chief Executive Officer & DirectorJebediah LedellChief Operating OfficerErick J. LuceraChief Financial OfficerMatthew CoulterVice President-Information TechnologyStefanie SolomonHead-ComplianceKey CompetitorsLexicon PharmaceuticalsNASDAQ:LXRXXOMANASDAQ:XOMAVerastemNASDAQ:VSTMVanda PharmaceuticalsNASDAQ:VNDARigel PharmaceuticalsNASDAQ:RIGLView All Competitors AVEO Stock Analysis - Frequently Asked Questions How were AVEO Pharmaceuticals' earnings last quarter? AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.06. The biopharmaceutical company had revenue of $15.17 million for the quarter, compared to the consensus estimate of $14.29 million. AVEO Pharmaceuticals had a negative net margin of 30.79% and a negative trailing twelve-month return on equity of 81.66%. During the same period in the prior year, the company posted ($0.33) earnings per share. When did AVEO Pharmaceuticals' stock split? Shares of AVEO Pharmaceuticals reverse split on Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO? 4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend. What other stocks do shareholders of AVEO Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA). This page (NASDAQ:AVEO) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsYou won't believe what Citigroup just did to it's depositorsAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AVEO Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.